Skip to main content
Premium Trial:

Request an Annual Quote

Quest Licenses Clinical Genomics' Biomarkers

NEW YORK (GenomeWeb News) – Quest Diagnostics has licensed Clinical Genomics' biomarkers associated with colorectal cancer in order to develop them as a detection tool, Clinical Genomics said today.

Under the two-year agreement, Clinical Genomics will receive milestone payments to allow Quest Diagnostics to develop the gene-based portfolio to detect precancerous and cancerous colorectal tumors. Quest's rights under the pact are worldwide and exclusive.

Quest Diagnostics also made an equity investment in Clinical Genomics of an undisclosed sum.

Quest Diagnostics in 2006 acquired Enterix, a maker of the Food and Drug Administration-cleared InSure fecal immunochemical test for aiding the detection of colorectal cancer based on stool testing. Clinical Genomics is a spinoff of Enterix.

Clinical Genomics said it discovered the markers through a collaboration with Flinders University of South Australia and the Australian Government's Commonwealth Scientific and Industrial Research Organization, and that they "show promise as aids in detection of both colorectal cancer and precancerous adenomas."

Further financial terms of the agreement were not released.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.